Back to top
more

Perrigo (PRGO)

(Real Time Quote from BATS)

$24.29 USD

24.29
369,801

+0.04 (0.17%)

Updated Oct 11, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Is Koninklijke Philips (PHG) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Perrigo (PRGO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.

Perrigo (PRGO) Q1 Earnings and Revenues Top Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 2.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Viemed Healthcare, Inc. (VMD) Misses Q1 Earnings Estimates

Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -42.86% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Green Thumb Industries Inc. (GTBIF) Q1 Earnings and Revenues Lag Estimates

Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -33.33% and 0.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales

Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.

Perrigo (PRGO) Tops Q4 Earnings Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Perrigo (PRGO) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Baxter International (BAX) Lags Q4 Earnings Estimates

Baxter (BAX) delivered earnings and revenue surprises of -6.38% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 7.59% and 4.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Down 1.5% Since Last Earnings Report: Can It Rebound?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View

Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.

Perrigo (PRGO) Misses Q3 Earnings and Revenue Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -15.15% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate PetIQ (PETQ) to Report a Decline in Earnings: What to Look Out for

PetIQ (PETQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill

The FDA schedules a joint advisory committee meeting in November 2022 to review Perrigo's (PRGO) regulatory filing for the first-ever over-the-counter birth control pill.